Across TCGA pan-cancer cohorts, SORBS1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SORBS1 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher SORBS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SORBS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
THYM, UCEC, and STAD are the cancer types where SORBS1 Mutation most reproducibly stratifies survival.